dsip-safety-data DSIP DSIP 5mg | Sleep Neuropeptide

Watermann I, Schmitt B, Stellmacher F, Mller J, Gaber R, Kugler C, et al

Updated July 24, 2026 at 8:55 AM PDT For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter

That is the main thing I look for when ordering peptides. Daniel Reed Dihexa High-Affinity Hepatocyte Growth Factor Modulator Dihexa is a small-molecule peptide analogue investigated for its high-affinity interaction with the hepatocyte growth factor (HGF) and c-Met receptor system

These receptors are expressed in various tissues and cells, enabling VIP to exert its pleiotropic effects

Key gaps include: No large-scale randomised controlled trials in humans the evidence basis for clinical use is extrapolated from animal data and small pilot studies No long-term safety data effects beyond 1216 weeks are not well characterised Variable results in human sleep trials some early human studies showed modest or inconsistent effects on sleep architecture compared to animal data, suggesting the translation may not be linear No FDA approval DSIP is not approved for any therapeutic use in the United States Stability concerns DSIP degrades relatively quickly in circulation